Awaiting development: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 281 to 290 of 295

TitleType
Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295]Technology appraisal guidance
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]Technology appraisal guidance
Vilobelimab for treating COVID 19 TS ID 11815Technology appraisal guidance
Virtual Wards for COPD exacerbationsMedical technologies guidance
Virtual Wards for Heart FailureMedical technologies guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]Technology appraisal guidance
Vosoritide for treating achondroplasia in people 4 months and over ID6488Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All